DSpace Repository

An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean

Show simple item record

dc.contributor.author Salas-Hernández, A.
dc.contributor.author Galleguillos, M.
dc.contributor.author Carrasco, M.
dc.contributor.author López-Cortés, A.
dc.contributor.author Redal, M.A.
dc.contributor.author Fonseca-Mendoza, D.
dc.contributor.author Esperón, P.
dc.contributor.author González-Martínez, F.
dc.contributor.author Lares-Asseff, I.
dc.contributor.author Lazarowski, A.
dc.contributor.author Loera-Castañeda, V.
dc.contributor.author Remírez, D.
dc.contributor.author Martínez, M.F.
dc.contributor.author Vargas, R.
dc.contributor.author Rios-Santos, F.
dc.contributor.author Macho, A.
dc.contributor.author Cayún, J.P.
dc.contributor.author Perez, G.R.
dc.contributor.author Gutierrez, C.
dc.contributor.author Cerpa, L.C.
dc.contributor.author Leiva, T.
dc.contributor.author Calfunao, S.
dc.contributor.author Xajil, L.
dc.contributor.author Sandoval, C.
dc.contributor.author Suárez, M.
dc.contributor.author Gonzalez, A.
dc.contributor.author Echeverría-Garcés, G.
dc.contributor.author Sullón-Dextre, L.
dc.contributor.author Cordero-García, E.
dc.contributor.author Morales, A.R.
dc.contributor.author Avendaño, A.
dc.contributor.author Sánchez, E.
dc.contributor.author Bastone, L.C.
dc.contributor.author Lara, C.
dc.contributor.author Zuluaga-Arias, P.
dc.contributor.author Soler, A.M.
dc.contributor.author Da Luz, J.
dc.contributor.author Burgueño-Rodríguez, G.
dc.contributor.author Vital, M.
dc.contributor.author Reyes-Reyes, E.
dc.contributor.author Huaccha, A.
dc.contributor.author Ariza, Y.V.
dc.contributor.author Tzul, N.
dc.contributor.author Rendón, A.L.
dc.contributor.author Serrano, R.
dc.contributor.author Acosta, L.
dc.contributor.author Motta-Pardo, A.
dc.contributor.author Beltrán-Angarita, L.
dc.contributor.author Brand Alarcón, Erika Tatiana
dc.contributor.author Jiménez, M.A.
dc.contributor.author Hidalgo-Lozada, G.M.
dc.contributor.author Romero-Prado, M.M.J.
dc.contributor.author Escobar-Castro, K.
dc.contributor.author Umaña-Rivas, M.
dc.contributor.author Vivas, J.D.
dc.contributor.author Lagos, P.
dc.contributor.author Martínez, Y.B.
dc.contributor.author Quesada, S.
dc.contributor.author Calfio, C.
dc.contributor.author Arias, M.L.
dc.contributor.author Lavanderos, M.A.
dc.contributor.author Cáceres, D.D.
dc.contributor.author Salazar-Granara, A.
dc.contributor.author Varela, N.M.
dc.contributor.author Quiñones, L.A.
dc.contributor.author On behalf of the RELIVAF NETWORK
dc.date.accessioned 2023-07-18T16:18:56Z
dc.date.available 2023-07-18T16:18:56Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/13927
dc.description.abstract Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC. en_US
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartofseries Frontiers in Pharmacology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Pharmacogenomics en_US
dc.subject Gene/drug pair en_US
dc.subject Barriers en_US
dc.subject Precision medicine en_US
dc.subject.mesh Farmacogenética
dc.subject.mesh Genes
dc.subject.mesh Preparaciones Farmacéuticas
dc.subject.mesh Medicina de Precisión
dc.title An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.3389/fphar.2023.1175737
dc.relation.issn 1663-9812


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics